<DOC>
	<DOCNO>NCT00146588</DOCNO>
	<brief_summary>The purpose study find effect ( good bad ) combination cytoxan , epirubicin , capecitabine woman Stage II/II/IIIA breast cancer .</brief_summary>
	<brief_title>Cytoxan , Epirubicin Capecitabine Women With Breast Cancer</brief_title>
	<detailed_description>- Each treatment cycle last 21 day patient participate least 4 cycle , 6 cycle treatment . - Patients receive cytoxan ( cyclophosphamide ) epirubicin intravenously day 1 treatment cycle . On day 4-17 cycle , patient take capecitabine orally twice day . - While study patient require complete diary capecitabine treatment . - Blood test perform week along survey begin trial certain follow-up visit evaluate patient 's experience oral chemotherapy . - Patients treatment 12-18 week depend upon whether disease progress patient develops inacceptable side effect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histologically confirm Stage IIII breast cancer . If Stage I , deem sufficiently high risk develop recurrent disease warrant participation . 18 year age old ANC &gt; 1,000/mm3 Platelet count &gt; 100,000/mm3 Hemoglobin &gt; 10 Creatinine &lt; 2.0 SGOT &lt; 2 x ULN Bilirubin &lt; 1.5mg/dl Able swallow retain oral medication LVEF great equal 50 % ECOG performance status 0 1 Pregnant lactate Prior malignancy within 5 year ( exclude squamous basal cell skin cancer ) Prior chemotherapy within 5 year Prior anthracycline therapy Serious comorbid physical psychological condition</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>cytoxan</keyword>
	<keyword>epirubicin</keyword>
	<keyword>capecitabine</keyword>
</DOC>